Overactive Bladder Clinical Trial
Official title:
A Prospective Efficacy Study Comparing FREquency of Use and Efficacy of a Personalized Surgery-free Wearable and Personalized Bladder Modulation System With Objective Confirmation of Nerve Activation for Use in the Home by Subjects With OverActive Bladder Syndrome
Verified date | June 2024 |
Source | Avation Medical, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, multicenter study that was conducted to evaluate the safety and efficacy of a novel, closed-loop, continuous-sensing wearable neuromodulation system for Overactive Bladder symptom control. The end points were refined based on FDA feedback and the data was analyzed post-hoc based on these endpoints, combining the group into a single study arm.
Status | Completed |
Enrollment | 96 |
Est. completion date | June 15, 2023 |
Est. primary completion date | October 8, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female and 18 years of age or older at the time of enrollment 2. Willing and capable of giving informed consent 3. Willing and able to comply with study-related requirements and procedures 4. Are an appropriate candidate for the system required in this study based on the clinical judgment of the Investigator. 5. Have been diagnosed or have symptoms of OAB for at least 3 months Page 8 of 30 Version 1.0 dated July 06, 2020 prior to enrollment 6. Have an average of 10 or more frequency events per day in a 3-Day Voiding Diary 7. Able to provide clear, thoughtful responses to questions and questionnaires 8. Able to toilet self and have and maintain personal hygiene 9. Able to don and doff the bladder modulation garment on their ankle area, replace Gel Pads and use the controller 10. Have ankle and foot anatomy that allows the garment to fit properly, including having the hook and loop closures close and without excessive gapping and allowing the electrodes to fit firmly on the skin. 11. Able to sense and tolerate stimulation for the entire 30-minute therapy session 12. Has detectable EMG signal in response to modulation system stimulation during an investigator supervised screening session 13. If currently on medications that may affect their OAB symptoms, is on a stable dose (no new, discontinued, or change in dose) of all prescribed medication for at least 4 weeks prior to enrollment 14. Female subjects of child-bearing potential must have a negative urine dip stick pregnancy test at baseline 15. Have access to Wi-Fi at least weekly 16. Are capable of using the tablet-based controlling app Exclusion Criteria: 1. Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcomes, in the opinion of the investigator. 2. Allergic, or have shown hypersensitivity, to any materials of the system which come into contact with the body 3. Have a pacemaker or implanted defibrillator 4. Have a documented current or reoccurring Urinary Tract Infection (3 or more in the 12months prior to enrollment) 5. Current use of a marketed device for treatment of their OAB or incontinence (including but not limited to Interstim®) 6. Have had Botox treatment for their OAB in the previous 8 months 7. Current use of transcutaneous electric nerve stimulation (TENS) in pelvic region, back or legs 8. Had PTNS treatment within 6 months prior to enrollment 9. Use of investigational drug/device therapy within past 12 weeks 10. Is concomitantly participating in another clinical study 11. Had within 6 months of enrollment a significant untreated substance abuse disorder or polysubstance abuse disorder stemming from dependency producing medications, alcohol, and/or illicit drugs 12. Pregnant or planning to become pregnant within the next 12 weeks 13. Has scar tissue, metal, or other implant in the target ankle that would interfere with stimulation 14. Has a neurological disorder that causes abnormal sensations in the lower leg (loss of sensation or allodynia) 15. Has a neurological disorder that affects the bladder or a diagnosis of interstitial cystitis, radiation cystitis, or fistulas. 16. Has a skin condition in the area of the ankle stimulation location that would preclude them from using surface stimulation 17. Has been diagnosed with incontinence due to neurogenic bladder 18. Have failed a third line treatment for their OAB because of lack of effectiveness in the last 2 years (PTNS, Botox, or SNS) 19. Urge incontinence due to stress predominant mixed urinary incontinence (greater that 60% of the time) 20. Have polyuria (>2500 cc urine output per day) 21. Has urinary retention or incomplete bladder emptying 22. Has symptoms of benign prostatic hyperplasia (BPH -weak stream, straining, hesitancy or intermittency) |
Country | Name | City | State |
---|---|---|---|
United States | The Pelvic Solutions Center | Denver | Colorado |
United States | Colorado Pelvic Floor Consultants | Englewood | Colorado |
United States | Urology of Indiana | Greenwood | Indiana |
United States | West Virginia University | Morgantown | West Virginia |
United States | Ochsner Medical Center | New Orleans | Louisiana |
United States | Women's Health Institute | Oak Lawn | Illinois |
United States | Michigan Institute of Urology | Saint Clair Shores | Michigan |
United States | Stanford University | Stanford | California |
United States | Tranquil Medical Rsearch | Webster | Texas |
Lead Sponsor | Collaborator |
---|---|
Avation Medical, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Responders in Voiding (Urinary Frequency) Events | The proportion of responders in voiding (urinary frequency) events, where a responder is defined as a subject that either achieves a 50% or greater reduction, from baseline (Visit 1) to Week 12 (Visit 5), in total voids per day relative to an upper normal limit of 8 voids per day, or returns to normal (8 or fewer voids per day) at Week 12. | 12 Weeks | |
Secondary | System-Related Adverse Events | Number of System Related Adverse Events from Baseline to 12 Weeks | 12 Weeks | |
Secondary | Proportion of Responders in Incontinence (Leak) Events (IE) | Proportion of Responders in Incontinence (Leak) Events (IE), where a responder is defined as a subject that either achieves a 50% or greater reduction, from baseline (Visit 1) to Week 12 (Visit 5), in total incontinence events per day, or returns to normal (0 events per day), at Week 12. | 12 Weeks | |
Secondary | Proportion of Responders in Urgency Events (UE) | Proportion of Responders in Urgency Events (UE), where a responder is defined as a subject that either achieves a 50% or greater reduction, from baseline (Visit 1) to Week 12 (Visit 5), in total urgency events per day, or returns to normal (0 events per day) at Week 12. | 12 Weeks | |
Secondary | Overall Responder Rate at 12 Weeks | Overall Responder Rate at 12 Weeks, where responder is defined as any subject with a 50% or greater improvement, or return to normal, in the total number of voids per day, or the total number of urgency events/day, or the total number of leaks per day from baseline at Week 12. | 12 Weeks | |
Secondary | Overall Responder Rate at 6 Months | Overall Responder Rate at 6 Months, where responder is defined as any subject with a 50% or greater improvement, or return to normal, in the total number of voids per day, or the total number of urgency events/day, or the total number of leaks per day from baseline at 6 months. | 6 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Completed |
NCT00928070 -
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
|
Phase 4 |